The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro. Related Experimental Eli Lilly weight loss drug proves promising for type 2 diabetics Eli ...

Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling compounded versions of its blockbuster GLP-1/GIP receptor agonist tirzepatide ...